Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP712216.RAVsxROs_XobcJg0p67mVsoN58zRNwqHZoWWBHvyTKoIQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP712216.RAVsxROs_XobcJg0p67mVsoN58zRNwqHZoWWBHvyTKoIQ130_assertion type Assertion NP712216.RAVsxROs_XobcJg0p67mVsoN58zRNwqHZoWWBHvyTKoIQ130_head.
- NP712216.RAVsxROs_XobcJg0p67mVsoN58zRNwqHZoWWBHvyTKoIQ130_assertion description "[The evidence for prostate cancer risk reduction with the mono 5?-reductase inhibitor (5ARI) finasteride in a low-risk population and, more recently, with the dual 5ARI dutasteride in a population at increased risk of developing the disease, has potential to expand management options for men at risk of developing prostate cancer beyond more frequent and/or earlier surveillance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP712216.RAVsxROs_XobcJg0p67mVsoN58zRNwqHZoWWBHvyTKoIQ130_provenance.
- NP712216.RAVsxROs_XobcJg0p67mVsoN58zRNwqHZoWWBHvyTKoIQ130_assertion evidence source_evidence_literature NP712216.RAVsxROs_XobcJg0p67mVsoN58zRNwqHZoWWBHvyTKoIQ130_provenance.
- NP712216.RAVsxROs_XobcJg0p67mVsoN58zRNwqHZoWWBHvyTKoIQ130_assertion SIO_000772 21166744 NP712216.RAVsxROs_XobcJg0p67mVsoN58zRNwqHZoWWBHvyTKoIQ130_provenance.
- NP712216.RAVsxROs_XobcJg0p67mVsoN58zRNwqHZoWWBHvyTKoIQ130_assertion wasDerivedFrom befree-20150227 NP712216.RAVsxROs_XobcJg0p67mVsoN58zRNwqHZoWWBHvyTKoIQ130_provenance.
- NP712216.RAVsxROs_XobcJg0p67mVsoN58zRNwqHZoWWBHvyTKoIQ130_assertion wasGeneratedBy ECO_0000203 NP712216.RAVsxROs_XobcJg0p67mVsoN58zRNwqHZoWWBHvyTKoIQ130_provenance.